SEC Form 4 · accession 0000882104-17-000020
PDL BIOPHARMA, INC. · PDLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Peter McLaughlin
Officer — President, CEO
Period of report
Mar 4, 2017
Accepted (ET)
Mar 7, 2017 · 8:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882104
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Mar 4, 2017 | A | 588,235 | $2.04 | A | 1,404,463 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved, based upon the following schedule: 50% on December 2018; 16.66% on December 2019; 16.66% on December 2020; and 16.66% on December 2021.